0001104659-22-067880 8-K 12 20220602 5.07 20220603 20220603 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 8-K 34 001-39202 22993002 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 8-K 1 tm2217603d1_8k.htm FORM 8-K 0001477845 false 0001477845 2022-06-02 2022-06-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2022 ANNOVIS BIO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-39202 26-2540421 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) File Number) Identification No.) 1055 Westlakes Drive, Suite 300 Berwyn, PA 19312 (Address of Principal Executive Offices, and Zip Code) (610) 727-3913 Registrant’s Telephone Number, Including Area Code Not Applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value ANVS New York Stock Exchange $0.0001 per share Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x Item 5.07 Submission of Matters to a Vote of Security Holders On June 2, 2022, Annovis Bio, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). All matters voted upon at the Annual Meeting were approved with the required votes. The matters that were voted upon at the Annual Meeting, and the number of votes cast for or against, as well as the number of abstentions and broker non-votes, as to each such matter are set forth below. 1. Election of Directors. The following director nominees were elected to serve as directors of the Company, with the following votes tabulated: For Withheld Broker Non-Vote Michael Hoffman 3,294,037 152,137 2,249,648 Maria Maccecchini 3,439,842 6,332 2,249,648 Claudine Bruck 3,338,616 107,558 2,249,648 Reid McCarthy 3,414,636 31,538 2,249,648 Mark White 2,572,013 874,161 2,249,648 2. Ratification of the appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December 31, 2022. The appointment of WithumSmith+Brown, PC as our independent registered public accounting firm for the fiscal year ending December 31, 2022 was ratified, with the following votes tabulated: For Against Abstain Broker Non-Vote 5,674,126 5,920 15,776 - SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: June 3, 2022 By: /s/ Jeffrey McGroarty Name: Jeffrey McGroarty Title: Chief Financial Officer